To predict flare-ups and assess disease activity in SLE, elevated levels of anti-double-stranded DNA antibodies (anti-dsDNA) and erythrocyte sedimentation rate, as well as decreased complement levels (C3 and C4), are commonly used [22]. This evidence concerns the gene C3 and systemic lupus erythematosus.